Health Care·Biotechnology·$2.2B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.36 | N/A | -80.00% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.36 | N/A | -80.00% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management acknowledged the difficulties faced this quarter and emphasized their commitment to ongoing projects. They did not offer any forward guidance.
Management did not provide specific guidance for future performance.
The company is focused on advancing its pipeline despite the current challenges.
Tyra Biosciences reported a significant loss per share, which was below expectations, leading to a 4.59% drop in stock price. The lack of revenue figures and guidance may raise concerns among investors about the company's future performance. The management's cautious tone suggests they are navigating challenges but remain focused on their pipeline.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
ENTERPRISE PRODS PAR
May 2, 2022